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ABSTRACT 
Objective: Because dopamine functioning varies by sex and age it might be expected that the 
effects of methylphenidate or amfetamine, the psychostimulants used for the treatment of 
Attention Deficit /Hyperactivity Disorder (ADHD), will also be moderated by these factors. 
Here we review the published literature on whether stimulant effects in ADHD symptoms 
vary by age and sex. 
Method: We searched for studies published between 1989 until October 2009. Databases 
searched included U.S. National Library of Medicine (PubMed), Medline, EMBASE, 
PsycINFO and ISI Web of Knowledge. Firstly, we reviewed the effects of stimulant drugs on 
male and female patients and patients of pre-school, middle childhood, adolescence and 
adulthood. Secondly, we reviewed studies that directly tested the moderating effect of age 
and sex.  
Results: Randomised controlled trials confirm that stimulant medication is efficacious for, 
and well tolerated by, males and females and patients across the age range; although 
preschoolers appear to have a less beneficial response and more side effects. Few studies that 
specifically examined the moderating effect of age and/or sex were identified. For sex, no 
effects on overall response were found, although one study reported that sex moderated 
methylphenidate pharmacodynamics.  The few effects found for age were small and 
inconsistent.  
Conclusions: The available evidence suggests that stimulant medication, when appropriately 
administered, has efficacy as an ADHD treatment for both sexes and across all ages. There 
are currently too few published papers examining the effects of sex and age to draw strong 
conclusions about moderation. Further studies of the pharmacodynamics of stimulants on 
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symptoms measured using objective tests in the laboratory or classroom setting need to be 
undertaken.  
Key words: methylphenidate, amfetamine, psychostimulants, treatment response; sex; 
gender, age; attention deficit hyperactivity disorder; ADHD; psychopathology; medication; 
moderation; prediction. 
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1. INTRODUCTION 
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic and impairing 
disorder, marked by a pervasive and persistent pattern of inattention, overactivity and 
impulsiveness; affecting around five percent of the population of children and adolescents.  It 
is associated with significant costs to patients, families and society, as well as burden to 
social and health care services [1]. Over the long term, untreated ADHD is associated with 
school failure, delinquency and substance abuse [2-5]. 
Stimulant and non-stimulant treatments for ADHD: A combination of pharmacological 
and psychological therapies are recommended for the treatment of ADHD [6, 7]; and a 
number of different medications (stimulants and non-stimulants) which are licensed in the US 
and Europe have been shown to have both efficacy and tolerability. This review of sex and 
age effects on treatment response will focus on stimulant medications.  
Stimulant medications are considered a first line of treatment for ADHD [6, 7] leading to a 
clinically significant reduction of symptoms in around 70 percent of cases [8-10].  In 
addition, they have also shown some efficacy in the treatment of other conditions, such as 
narcolepsy and resistant depression [11, 12]. There are two main classes of stimulants used to 
treat ADHD; methylphenidate (MPH) and amfetamine (AMF).  
MPH is available in several formulations, with different delivery mechanisms that result in 
varying pharmacokinetic (PK) profiles and different patterns of symptom control across the 
day [13]. Immediate release (IR) MPH, which has been available for over 50 years and was 
the mainstay of ADHD treatment for a long time, is associated with a rapid onset of action 
(around 30 minutes post dose) and relatively rapid offset [around 4 hours post dose; 14].  
Consequently, IR MPH needs to be taken several times a day for adequate symptom cover. 
Swanson and colleagues [summarised in, 13] investigated the potential for developing an 
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effective ‘once a day extended release (ER) preparation’, and as a result of this there are now 
various oral ER preparations, several of which are licensed in European countries (e.g. 
Concerta XL, Equasym XL, Medikinet XL and Ritalin LA). These preparations use various 
technologies to deliver an initial IR bolus followed by an ER dose designed to last for either 8 
or 12 hours post dose. There is also, in the US but not Europe, a MPH transdermal patch 
technology that facilitates a more flexible ER delivery [15]. The relationship between the PK 
and pharmacodynamics (PD) of MPH is complex and incompletely understood; however 
recent studies have suggested that the main clinical effects closely follow the predicted PK 
profiles [16, 17]. 
The precise pharmacological mechanism of action of MPH is currently unknown, with some 
of the most fundamental issues being debated. It is understood that MPH results in increased 
levels of extra-cellular dopamine (DA) by blocking DA transporters (DAT) [18]. Grace 
(2001) has proposed that these increased levels of tonic extrasynaptic DA may stimulate 
impulse regulating DA autoreceptors resulting in a decrease in phasic DA release and phasic 
DA levels [19]. On the other hand, Volkow and colleagues (2001) have proposed that the 
blocked DAT overcomes the inhibitory effects on the autoreceptors, resulting in a net 
accumulation of DA in the synapse and amplification of DA signals from both tonic and 
phasic DA cell firing [20]. It has also been demonstrated that concentrations of other 
neurotransmitters, such as norepinephrine (NE) and serotonin (5-HT) are also elevated 
following MPH administration [21-23].   
In addition to reducing the core ADHD symptoms, MPH treatment is often, but not 
inevitably, associated with a reduction in comorbid oppositional defiant disorder (ODD) and 
conduct disorder (CD) symptoms [24, 25]. The impact of MPH on neuropsychological 
functioning is complex. Whilst several studies have reported that MPH is associated with 
enhanced executive functioning [26] others using a double-blind randomised controlled 
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methodology have found an improvement on tasks with low but not high executive demands 
[27]. Findings from a recent study suggest that MPH increased preference for delayed reward 
in ADHD patients [28]. Females are known to report markedly different subjective effects to 
psychostimulants than men; furthermore, they also progress to drug dependence more rapidly 
(Kosten et al., 1996; McCance-Katz et al., 2005). Differences in reward-related neural 
function between men and women have been reported (Dreher et al., 2006).  One study has 
reported an independent main effect for age between ADHD cases and their non ADHD 
controls in a number of tasks which assess delay aversion [DAv; 29]. This main effect was 
reported to be significant on all assessment measures with children (6 – 12 years) having 
worse performance than adolescents (13 – 17 years). For example, using the The Maudsley’s 
Index of Childhood Delay Aversion assessment [30] younger children were less likely to 
choose long delayed reward compared to adolescents . This is in line with DAv Theory – 
which makes a number of specific predications about the effects of reward delay in particular 
contexts. These predictions are derived from the theory that delay-related effects are 
associated with alterations in the signalling of delayed rewards, and are compounded by an 
acquired motivation to escape or avoid delay. This is hypothesized to be conditioned over 
time in response to repeated exposure to social situations and failure in delay-rich settings 
experienced by children with altered delay reward signalling [31]. 
There are several AMF products licensed for use in ADHD; mixed amfetamine salts 
(Adderall), dextromethamfetamine (Desoxyn), dextroamfetamine (Dexedrine) and a 
dexamfetamine pro-drug lisdexamfetamine (Vyvanse).  Whilst all of these medications are 
available in the United States, only immediate release dexamfetamine is licensed for use in 
Europe and even then it is widely available in the United Kingdom alone. As with MPH both 
IR (e.g. Adderall, Desoxyn and Dexedrine) and ER (Adderall XR) preparations are available. 
The dexamfetamine pro-drug lysdexamfetamine (Vyvanse) also lasts for around 12 hours and 
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can be given as a once daily preparation. These agents also act by blocking DA reuptake and 
stimulating the release of DA into the synapse. Whilst they work in a similar way as MPH 
there are also differences between the two types of drugs (AMF stimulate DA release as well 
as block reuptake) and as a consequence a proportion of those who respond to MPH do not 
respond to AMF and vice versa [10]. AMF has been shown to influence neurotransmitter 
activity selectively in brain regions that are predominantly involved in reward processing 
[i.e., striatum, ventral striatum and nucleus accumbens; 28, 32].   
Although they have different profiles of action across the day, when they are given in 
equivalent daily doses long acting formulations of MPH and AMF have been demonstrated to 
be equipotent compared to the IR preparations [33]. Both MPH and AMF appear to be 
equally effective in children with and without comorbid problems [34-36] and other disorders 
such as chronic fatigue syndrome [37] and depression [38]. Although both stimulants are 
generally well tolerated with common side effects including slight growth slowing, sleep 
problems and reduced appetite [39 in press], more serious side effects relating to psychiatric 
and cardiac problems can occur, but are rare [40, 41]. A number of non-stimulants have also 
been shown to be efficacious for the treatment of ADHD [42] however, they will not be 
discussed further as this review will focus solely on stimulants.  
Predicting stimulant drug response: Given that not all patients respond to stimulant 
medication it would be helpful to identify which factors predict either a good response to 
ADHD pharmacological treatment or increase the risk of adverse events.  Firstly, although 
normalization of symptoms does occur and is an appropriate goal for treatment [43] not 
everyone who responds benefits from complete symptom reduction. For example, Coghill et 
al. (2007) reported that whilst 70% of subjects had a robust and clinically significant response 
to MPH, only 56% had post treatment scores within the normal range [27]. Secondly, a 
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proportion of those who respond well to stimulant medication are unable to continue to take it 
due to intolerable adverse effects [41]. Furthermore, the presence of milder adverse events 
can result in poor compliance, reduced confidence in medication treatment by parents of 
young children [44] and low adherence especially during adolescence [45]. Finally, as the 
overall response rates to MPH and AMF are similar. For example, approximately 70% of 
patients respond to each independent drug and 25% respond to one but not the other, meaning 
that 95% respond to at least one [10]. It would be helpful for clinicians to be able to predict; 
(i) which patients are more likely to respond to a particular stimulant and; (ii) those who 
would be less likely to respond to either. Clearly, there are a number of possible biological 
and clinical factors that might be important, such as clinical presentation including symptom 
severity and genetic predisposition. Few studies have systematically studied multiple 
predictors of response and these have tended to report contradictory findings. For example, 
whilst both Taylor et al. (1987) and Buitelaar et al. (1995) found younger age to be a positive 
predictor of clinical response to MPH, the study of Taylor observed greater pre-treatment 
attentional impairment, and hyperactivity, poor performance on attentional tests lower IQ 
scores, and clumsiness in ‘responders’. Buitelaar et al. (1995) however, found the opposite 
pattern of effects with respect to attentional impairment, hyperactivity and IQ, furthermore it 
was also revealed that responders were more likely than non-responders to have anxiety 
related difficulties [46]. Santosh et al. (2005) found that, compared to the DSM-IV diagnosis 
of combined type ADHD, the ICD-10 diagnosis of Hyperkinetic disorder, that describes a 
group with severe, pervasive and impairing ADHD, was predictive of a more robust response 
to medication than to behavioural treatments. 
 In the current paper we review published data examining two potential moderators of 
stimulant response; sex and age.  
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Sex - a candidate moderator of stimulant response:  Several factors make sex a candidate 
moderator of stimulant response in ADHD.  Clinically, females differ from males in terms of 
the prevalence of ADHD [47].  Population based studies commonly report the prevalence of 
ADHD as between two and four times greater for males than it is for females [48, 49]. 
Interestingly, findings from clinic based studies suggest that girls with ADHD are less likely 
to be referred than boys, as ADHD is diagnosed between six to nine times more often in 
males than females [7, 50]; whilst this is likely to reflect different patterns of comorbidity and 
referral biases, it does suggest that there may be considerable clinical differences between 
community and clinic based samples and that even more caution than usual is required when 
translating findings from studies of one population to the other. Consequently, it is important 
to be careful when interpreting the results of clinical trials that tend to draw their subjects 
from clinic based samples, as differences (or lack thereof) could represent a Berkson type 
bias [51]. Males and females have also been shown to differ with respect to clinical 
presentation and symptom profiles, with females being reported to experience fewer of the 
externalising components of the disorder [52]. Nevertheless Novik et al. (2006) found that 
girls were as likely as boys to receive stimulant medication as an initial treatment for ADHD 
in a large European observational study [53].  
Sex differences have also been reported in pathophysiology. Anderson and Teicher (2000) 
demonstrated differences in DA receptor density between developing male and female rats 
whereby peri-adolescent male rats were more likely to show overproduction and subsequent 
pruning of striatal D2 receptors compared with periadolescent females [54].  Studies based on 
human samples have generally shown no differences in neuropsychological deficits between 
the sexes [e.g., 55].  
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Sex differences in the effects of psycho-active drugs in general [for a review see; 56] and 
stimulants in particular [e.g., 57, 58] are well established. There are well documented 
generalised differences between males and females in drug PK including drug metabolism 
[56], drug absorption [59] and distribution [60]. In addition, differences have also been 
reported in adverse drug reactions [61] and PD [PD; 62]. Certain sex-specific biological 
processes may also be relevant including changes in sex hormone levels [e.g., during 
pregnancy; 63]. Animal studies suggest that male and female brains might be organised 
differently to modulate an organism’s response to stimulants [64]. More specifically, it has 
been reported that the reinforcing effects of stimulants may be stronger in females than in 
males [65]. There is also animal and human evidence to suggest that there may be sex 
differences in DAT density and clearance of extracellular DA [66-69]. As noted above the 
differences in D1 and D2 receptor densities (e.g., the upregulation of male but not female 
striatal DA receptors) parallels the early developmental appearance of motor symptoms of 
ADHD [70]. Whilst these results are interpreted as a possible explanation for why ADHD 
prevalence rates are higher in men than women, they could also be relevant to medication 
response. Studies of adult women have identified lower plasma concentrations of MPH after 
weight based dosing, relative to men [71], suggesting that some women may require higher 
doses of MPH to achieve the same MPH plasma concentration as men [72]. Patrick et al. 
reported the extent of d-MPH exposure was greater in men when the IR dl-MPH was dosed 
without ethanol and when ethanol was administered before MPH. A difference was also 
observed when dl-MPH was dosed before ethanol; however this did not reach statistical 
significance. 
The extent of exposure (AUC) of d-MPH was significantly greater in men when the IR dl-
MPH was dosed without ethanol, as well as when ethanol was administered before MPH. 
This sex difference nearly reached significance when dl-MPH was dosed before ethanol. This 
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study did not examine the efficacy of MPH treatment between males and females however it 
did measure sex differences in the subjective effects of MPH with or without ethanol; 
findings revealed that females reported greater subjective effects than males, despite having 
lower dl-MPH C max and AUC values.  Such differences in sex based sensitivity toward drug 
stimulating effects is discussed and it is suggested that this could constitute a differential 
vulnerability to MPH abuse [71].  
 Fluctuations have also been reported to impact stimulant efficacy in post pubertal  [73] and 
adult females [74].  Sex differences in illicit drug use are demonstrated in the literature [for a 
recent review see 75].  Differences in striatal DA release following AMF administration have 
been reported in a reclopride positron emission tomography (PET) study in healthy adults, 
with males (n= 28) demonstrating markedly greater DA release than females (n= 15) . In a 
further sample of healthy adults, hormonal fluctuations in females have also been shown to 
affect AMF response [76].  
Age – a candidate moderator of stimulant response: There are a number of lines of 
evidence that suggest age should be considered as a potential moderator of stimulant effects 
on ADHD symptoms. It is well documented that ADHD is a lifespan condition [77] with 
many individuals continuing to experience symptoms and impairments from preschool 
through their adult years [78]. Although there are broad continuities with respect to ADHD 
symptoms patterns at the level of the individual case (i.e., a child with particular ADHD 
symptoms will often continue to experience similar symptoms throughout development), 
there are also often discontinuities with some children switching from one pattern of 
symptoms to another (e.g. from combined type to inattentive type or from 
hyperactive/impulsive type to combined type), in others the form of a symptom will change 
over time [e.g., from overt overactivity to inner restlessness; 77]. In the preschool period, 
symptoms of hyperactivity/impulsivity appear to predominate although this may reflect a 
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relative difficulty in observing or describing symptoms of inattention in children this age 
rather than an absence of problems [77]. In middle childhood through adolescence the classic 
combined type is the most common presentation with a full range of inattentive, hyperactive 
and impulsive symptoms present. During adult years attentional problems are often the most 
obvious as hyperactivity has been reported to be transformed into internal agitation [79]. 
Patterns of impairment and comorbidity also vary from age-to-age [80]. ADHD treatment 
outcomes have been documented in the literature for childhood, adolescent and adult 
treatment outcome [81, 82]. Apart from the Preschooler with ADHD Treatment (PATS) 
Study (Greenhill et al. 2006), little research has focused on treatment differences during the 
preschool period.  
Age differences in response to stimulants have also been documented in the animal literature. 
Canese et al. (2009) found that, whilst adult rats had an expected increase of functional 
magnetic resonance imaging (fMRI) BOLD signal in nucleus accumbens and prefrontal 
cortex with no effects in the hippocampus, in adolescent rats MPH induced a marked and 
generalised decrease of BOLD signal. These effects occurred earlier (< 12 minutes post 
dosing) in nucleus accumbens and prefrontal cortex, than they did in the hippocampus [83]. 
Furthermore, findings from a recent study suggest an increased threshold of behavioural 
activation following AMF treatment in adolescent rats, this has also been potentially related 
to changes in DA and the DA system during development [84]. There may also be age and 
sex differences in DAT binding and the relationships between this binding and verbal 
learning in humans; with women and younger participants having higher DA availability in 
caudate nucleus and better performance on verbal learning tasks [66]. Several reports have 
documented an age associated decline in DAT density [69, 85], with evidence of more 
functionally active DAT available in younger age groups [86].  
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Aim of the review: On the basis of these findings relating sex and age to DA function, both 
factors represent candidate moderators of stimulant drugs. The aim of the current review was 
to survey the literature to address two questions: (i) Do stimulant treatments for ADHD show 
efficacy and tolerability in both males and females and across age groups? And; (ii) within 
specific trials do age and sex moderate efficacy and tolerability of stimulants? Despite the 
obvious clinical importance of these questions, very few studies have addressed them directly 
[73, 87]. In fact until relatively recently most studies focused on pre-pubertal boys (age 6 – 
12 years). More recently studies have started to appear focusing on the preschool and 
adolescent and adult period.  
2. CURRENT REVIEW 
The current review focuses specifically on studies published over the past 20 years (between 
1989 until October 2009). Databases searched included U.S. National Library of Medicine 
(PubMed), Medline, EMBASE, PsycINFO and ISI Web of Knowledge. 
Literature of stimulant efficacy in different sex and age groups: Firstly, we identified 
randomised controlled trials (RCTs) of ADHD medication efficacy with; (i) male or female 
participants and; (ii) participants from each age sub-group (i.e., preschoolers, school age, 
adolescent and adult. For this literature search the following keywords were used to search 
databases: sex; gender; male; female; preschool; school age; adolescent; treatment; attention 
deficit/hyperactivity disorder (ADHD); randomised / randomized control trial (RCT); 
efficacy; and medication. 
Literature searches for moderating effects of age and sex on stimulant response: Secondly, 
we searched for studies of medication efficacy that included an assessment of age or sex as a 
moderator of treatment outcome within their analysis. For this literature search the following 
keywords were used to search databases: sex; gender; age; treatment; attention 
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deficit/hyperactivity disorder (ADHD); Methylphenidate (Ritalin, Concerta, Equasym, 
Metadate, Focalin, Medikinet, Attenta, Methylin, Rubifen, Biphentin and Daytrana); mixed 
amfetamine salts (Adderal); dexamfetamine (dexamfetamine, Dexedrine); and 
Lisdexamfetamine (Vyvanse). Relevant articles referenced in papers identified by this search 
were also included for review, and these in turn were used to identify additional reports. 
Moreover, pharmaceutical companies that currently market stimulant medication in Europe 
were also contacted and data was requested regarding the effects of age and sex on treatment 
outcome. Every effort has been made to provide as comprehensive a review as possible at the 
time of manuscript submission. For this second search (studies of medication efficacy that 
included an assessment of age or sex as a moderator of treatment outcome) a range of 
different designs were included (e.g., RCTs and observational studies).  
ARE STIMULANTS EFFICACIOUS FOR AND TOLERATED BY MALES AND 
FEMALES AND BY CHILDREN ACROSS THE AGE RANGE?  
Randomised controlled trials support the efficacy and tolerability of stimulants for both males 
and females and for patients of different ages from preschool to adulthood.  
Are Stimulants Efficacious and Well Tolerated by Both Sexes? Owing to the higher 
prevalence of ADHD in males the majority of medication trials have primarily enrolled boys 
and men. As a consequence the efficacy of stimulants within predominantly male samples has 
been well documented in the literature [87-92] reducing both ADHD symptoms and related 
aggression and hostility [93]. Despite evidence that in recent years prescriptions for ADHD 
medications have increased at a greater rate for females than for males [45], females continue 
to be less likely than males to receive stimulant medication for the treatment of ADHD [73, 
94]. In the UK the ratio of males to females receiving prescriptions for ADHD medications is 
around 66:1 which far exceeds both the gender ratio for ADHD in the population and the 
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referral ratio [45]. Research into the treatment response for females with ADHD has lagged 
behind that in males. For the purpose of this review we were unable to find any studies that 
included only female participants. Although, many of the recent RCTs conducted by the 
pharmaceutical companies to demonstrate efficacy of the newer ER preparations have 
enrolled reasonable numbers of female subjects, however few have reported the outcomes for 
females separate from those for the males. Studies that have reported on the efficacy of 
stimulants in females (based on subgroup analyses of RCTs conducted in mixed sex samples) 
suggest that stimulants are an effective treatment for ADHD in female patients. There are 
also positive results for studies using MPH [87, 91] mixed AMF salts [87, 95] and 
lisdexamfetamine [96]. In general these studies suggest that the tolerability and safety of 
stimulants is similar in females and males. Further studies investigating the efficacy and 
safety of stimulants in females must be considered a high priority in psychopharmacology 
research [87].  
Are stimulants efficacious and well-tolerated across the age range?  Despite the vast 
increase in the number of clinical trials over the past decade that have examined the efficacy 
of stimulants in the treatment of ADHD, the majority of these studies have continued to focus 
on middle childhood (i.e., 6-12 years). However, studies focusing on preschoolers, 
adolescents and adults have started to appear.    
Preschool: ADHD is increasingly being recognised as a valid disorder in the preschool period 
with treatment typically revolving around non-pharmacological options [7]. In most countries 
stimulant medications are not licensed for use in children younger than age 6 years, although 
dexamfetamine does have marketing authorisation for use with children as young as 3 years 
of age in the UK. Even though national and international guidelines for ADHD management 
do not recommend pharmacotherapy treatment for preschool children [6] use of stimulant 
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medications for ADHD children in the preschool years (age 3 to 6 years) is becoming more 
commonplace, albeit from a low base.  
In the United States, where the use of AMF products is more common than in Europe, MPH 
still accounts for over 90% of stimulant use in preschool children [97]. Only a small number 
of studies have investigated the efficacy of MPH in exclusively in preschool samples [98-
100, e.g., 101]. By far the most important and the largest of these studies is the ‘Preschooler 
with ADHD Treatment Study [PATS; 34].  Similar to other trials this study showed that 
although stimulants show efficacy in the preschool years, effect sizes are somewhat smaller 
and the numbers needed to treat is larger than those reported in school aged children. 
Moreover, tolerability was reported to be reasonable, with 11% of children dropping out 
because of intolerable adverse effects. Overall adverse effect profiles (e.g., crying, irritability 
and social withdrawal) appeared to be more pronounced and occurred at smaller doses than is 
usually seen in older children [102, 103].  It was also suggested that the acceptability of 
medication was lower in this age-group than for other age groups as retention rates were 
relatively low, with only 77 of the 183 preschoolers entering the medication phase of the trial 
[34]. Furthermore, there is particularly strong evidence of increased susceptibility to side 
effects for those preschool children with ADHD and comorbid developmental disabilities 
[100]. Although dexamfetamine is licensed for use in preschoolers in the UK we did not 
identify any RCTs that have specifically examined the efficacy of any AMF in preschool 
children. 
Middle Childhood: As mentioned above the majority of the trials have enrolled male 
participants in middle childhood. Both MPH and AMF are generally well tolerated and 
efficacious in approximately 70% of cases.   This evidence has been systematically reviewed 
on several occasions and will not be presented further [7, 104]. 
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Adolescence: Adolescent ADHD represents a particular treatment challenge because of; (i) 
increased problems with adherence [105] and; (ii) the emergence of complicated 
comorbidities, such as depression [104] and substance use disorder [SUD; 106]. Surprisingly, 
few studies have reported the efficacy of MPH in adolescent samples [107, 108]. In part, it is 
possible that this reflects the difficulties (and also the potential added cost) associated with 
recruiting and retaining adolescents in clinical trials. The overall findings from studies in this 
age group suggest that MPH continues to reduce the severity of the core symptoms of ADHD 
in adolescence [108]. Furthermore, the adverse event profile is similar to that observed in 
middle childhood [109]. Studies examining AMF in adolescent samples have similarly 
confirmed its efficacy and tolerability in this age group [110, 111]. Lack of adherence is a 
particular challenge in adolescence [45]. There are many potential factors which could 
explain this including, frustrations dealing with the occurrence of long term adverse drug 
reactions to stimulant use (e.g., headaches, and stomach pain [112] and/or a change in terms 
of demands of maintaining focus and concentration from the school setting to the workplace 
[105]. More evidence on medication safety and efficacy, and especially adherence and 
effectiveness, within adolescence is required given the high prevalence of comorbid mental 
disorders, multi-drug regimens and off-label use in this age group [113]. 
Adults: There is a growing body of evidence supporting the validity of the adult ADHD 
diagnosis [114] . Although the presentation of ADHD in adulthood may change, continuity 
has been reported between childhood, adolescent and adult ADHD. In addition to the core 
neurobiology also appearing to be similar, for example one study revealed smaller total 
cerebral brain volumes in ADHD patients from childhood through to adolescence [115] 
suggesting that genetic and/or environmental influences on brain development are fixed [77].  
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Both the British Association of Psychopharmacology guidelines [81] and the most recent 
NICE guidelines have recommended the use of stimulants for the treatment of adults with 
ADHD [7]. Despite this, a recent report has shown the prevalence of prescribing drugs to 
treat ADHD by general practitioners in the UK drops significantly for patients from age 15 to 
age 21 years [45] with very few individuals remaining on medication throughout this period. 
There are now several published RCTs which describe the efficacy of MPH in adult patients 
[95, 116-122]. Findings have revealed comparable effects of MPH in adults as those observed 
in children and adolescents [116, 120, 123]. There is also a similar safety profile [124]. One 
meta-analysis reported that the overall effect size of MPH treatment in adults was smaller 
than expected based on previous findings (d=0.42) in this area [122]; furthermore, this is also 
significantly lower than what has been generally reported in childhood. Fewer trials have 
been conducted which examine the role of AMF for the treatment of adult ADHD [125-127]. 
In general, these studies suggest that AMF is efficacious and is well tolerated in adult ADHD 
patients, with most treatment emergent adverse effects being of mild to moderate severity 
[127].  
DO SEX AND AGE MODERATE THE DEGREE OF STIMULANT RESPONSE?  
There is good evidence that both MPH and AMF are efficacious and tolerated by both males 
and females, and by patients of different ages. Here we turn to the question of whether there 
is evidence that the degree of efficacy or extent of adverse events varies by age and sex 
within studies. To answer this question it is important to identify studies that have sufficient 
power and range of participants of different ages and sex to allow a within subject statistical 
analysis. Unfortunately such studies are uncommon.  
Is there any evidence that sex is a moderator of stimulant response? The majority of 
research that has examined sex as a moderator of treatment response has focused on MPH. 
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Nine RCTs have been identified from the literature that examined the effect of a participant’s 
sex on stimulant response [10, 87, 91, 96, 128-131]. Three studies examined the effects of IR 
MPH.  The Multimodal Treatment of Children With ADHD study [90], compared 114 female 
ADHD patients and 165 male patients, aged 7-9 years [132]. This study reported no 
significant effects of sex as a moderator of drug effects on either symptom reduction or side 
effects. Barkley (1989) examined the effects of MPH on mother-child interactions in a 
sample of 20 girls and 20 boys (age 3 years 10 months – 10 years 1 month). The results of 
this study revealed no significant interactions between the sex and the dose effects of 
medication [130]. One study examined the effects of MPH on a sample of 12 boys (aged 5 
years 6 months – 11 years) and 12 girls [aged 5 years 8 months – 11 years 3 months; 129]. 
The results of this study revealed that girls responded to MPH in the same manner as an age 
and IQ matched group of boys. 
Three studies have looked at the moderating effects of sex on the efficacy of long acting 
MPH preparations; one in children [131] one in adolescents and young adults [87] and one in 
adults [128]. The Sonuga-Barke et al. (2007) study is based on the COMACS data, which is a 
study of the comparison of once-daily ER MPH formulations in children with ADHD in the 
laboratory school [17].  In this original study assessments were made by two trained 
observers during classroom sessions on the basis of a 1.5-hour cycle of activities, with 
separate assessments of attention and deportment being made at 0, 1.5, 3.0, 4.5, 6.0, 7.5, and 
then 12 hours following drug administration. In a reanalysis of this study data, Sonuga-Barke 
et al. (2007) compared 136 boys and 48 girls (aged 6 – 12 years) in a double-blind cross over 
trial of Concerta, MetadateCD/Equasym XL, or placebo, using a laboratory classroom setting 
with measurements of symptom change by trained observers across the day and overall 
response over the 7 day period as rated by the children’s parents using the Swanson, Nelson, 
and Pelham scale version IV [SNAP-IV; 133]. The results of this study revealed there was no 
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main effect of sex on either measure of overall response. Both sexes responded to MPH 
equally well however it remained possible that differential DA function and sex related PK 
differences could lead to different patterns of effect across the day, even where the average 
control across the whole day is the same. Interestingly compared with males, females had a 
statistically superior response at 1.5 hours after drug administration and an inferior response 
at the 12 hour time point [131]. A more recent study in a sample of adolescents (aged 16 – 18 
years) reported no sex differences in treatment response to either osmotic release MPH 
(OROS® MPH) and mixed AMF salts [se-AMF ER; 87]. In this study, response to 
medication was assessed for 16 females and 19 males using adolescent and parent ADHD 
rating scales (Conners Brief Rating Scale Revised, objective measures of inattention and 
hyperactive impulsive errors during a driving simulator task), neuropsychological tasks 
(Go/No-go test and the Delayed Matching-to-Sample Task) and an adolescent side effects 
rating scale (Stimulant Side Effects Rating Scale). No sex differences were evident on any 
measure although it is questionable whether the sample sizes were large enough to support a 
negative finding [87]. Ramos-Quiroga et al. (2009) investigated the predictors of response in 
a secondary analysis of data from a large RCT of long acting MPH in a group of adults (n = 
401) aged between 18 – 65 years of age, with a high proportion of female participants (46%). 
Unlike the other studies they found that whilst as a group both sexes responded better to 
MPH than placebo, being male was associated with a superior response at the end of the 
double blind phase of the study [128]. Two studies examined the effects of sex on response to 
both MPH and dexamfetamine (DEX) treatment of children with ADHD [91].  Efron and 
colleagues (1997) examined a group of 114 boys (mean age 105 months) and 11 girls (mean 
age 102.4 months). The findings from this study revealed that sex was not predictive of 
response to either stimulant [10]. One further study examined the effects of both MPH and 
DEX in a sample of 42 girls (age 6.2 – 12.7 years) and 56 boys [age 6.0 to 12.5 years; 91]. 
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The results of this study confirmed previous findings that females are comparable to males in 
terms of their response to treatment with both stimulants; with 95% of females responding 
well to one or both drugs.  Finally a recently completed lab-school study of lisdexamfetamine 
also concluded that there were no differences in overall response between male and female 
subjects [96]. 
As the studies by Sonuga-Barke et al. (2007) and by Wigal et al. (2009) employed a lab 
classroom design with multiple measures of efficacy across the day, it was possible to 
examine whether sex impacted on MPH and AMF PD. Wigal et al. (2009) employed an 
almost identical lab school design except that measures were taken at -0.5 hours pre-dose and 
then at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose.  However, this study found no 
sex differences with respect to PD of lisdexamfetamine. These results should be interpreted 
with caution due to the relatively small number of female participants (28 out of a total 
sample of 113 participants) compared to the somewhat larger Sonuga-Barke et al. (2007) 
sample (48 of a total of 184 participants). 
Is there any evidence that age is a moderator of stimulant effects?   
Few clinical trials have included a sufficiently broad age range to address this question 
adequately with most studies recruiting only in middle childhood (around the 6 – 12 year age 
range). However, six studies were identified from the literature that directly examined age as 
a moderator of stimulant treatment outcome in children and adolescents albeit often across a 
narrow age range [27, 46, 111, 134-136] and one in adults [128]. Whilst the findings from 
these studies are somewhat inconsistent, this is probably a consequence of the small numbers 
of participants in many studies and the limited age ranges of some. Taylor et al. (1987) 
conducted a double-blind, placebo-controlled, crossover trial of MPH and placebo with 
thirty-eight boys (6 – 10 years of age), referred for psychiatric treatment due to serious 
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behaviour problems. As not all subjects had either an ICD 9 or DSM III diagnosis of ADHD 
some caution is advised when interpreting the results. A good response was predicted by 
younger age as well as higher levels of inattentive and restless behaviour, impaired 
performance on tests of attention, clumsiness, and the absence of symptoms of overt 
emotional disorder. Diagnostic status (ICD 9 or DSM III) was not found to be a good 
predictor of MPH response [135]. Using a robust measure of response, Buitelaar et al. (1995) 
also found that young age predicted a stronger response to MPH in 46 children (aged between 
6 and 13 years). Strong response was also predicted by high IQ, considerable inattentiveness, 
low severity of disorder, and low rates of anxiety [46]. Using the same measures of response 
Coghill et al. (2007) did not find an effect of age on any measure of response in 3 x 4 week 
placebo-controlled, double-blinded, randomised, crossover trial of two dose levels of MPH 
(0.3 and 0.6 mg/kg/dose given twice daily and placebo) in 75 boys, aged 7–15 years with 
hyperkinetic disorder [27]. Pelham and colleagues (1991) compared the effectiveness of 
MPH treatment in a sample of all male children, 17 were between the ages 7 years 3 months 
to 10 years 11 months and a further 17 were adolescents between the ages of 12 years to 14 
years and 6 months. The findings of this study revealed treatment efficacy and tolerability to 
be similar in both age groups [136]. Findling and colleagues (2001) replicated these findings 
for both MPH and AMF in a randomised controlled crossover trial of these agents in 69 
young children (aged from 4 years  to 7.99 years), 56 youths (aged from 8 years to 10.99 
years) and 52 adolescents (aged from 11 years to 17.59 years); however, whilst both agents 
had similar efficacy in young children and adolescents, youths were found to benefit from 
smaller weight-adjusted doses than did the younger children [111]. In the study of Ramos-
Quiroga et al. (2009) described earlier, at the end of the double blind phase of the trial, older 
age (> 45 years) was associated with better treatment outcomes with long acting MPH than 
younger age [18 – 45 years; 128]. 
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DISCUSSION 
In this review we have investigated the evidence relating to the moderating effects of sex and 
age on the response of individuals with ADHD to stimulant medications. Such effects may be 
expected as a consequence of the sex and age related differences that have been shown in 
relation to DA function [69, 86, 137]. Two important general findings are: (i) notwithstanding 
the large number of clinical trials and other studies that support the efficacy, effectiveness, 
safety and tolerability of the stimulants MPH and AMF in the treatment of ADHD [7], 
relatively few studies have described the effects of sex and age on any of these outcomes; and 
(ii) taken together studies that have examined such effects suggest that stimulant medications 
are equally efficacious, effective, well tolerated by both males and females and by individuals 
from childhood through to adulthood: Evidence to date suggests that sex and age play a 
minimal role in moderating overall efficacy and safety of stimulants however further research 
is required in this area.  
These are important findings as ADHD is being increasingly recognised in females, 
adolescents and adults. Furthermore, whilst many of those with ADHD in these groups would 
benefit from treatment with stimulants, such treatment is (within Europe at least) relatively 
uncommon at the present time. The main proviso to this general message is that stimulants 
seem to be less efficacious for preschoolers and side-effects may be greater in this age group. 
The strongest evidence for this can be derived from the PATS study [e.g., PATS; 34] in 
which the effect sizes were smaller and there were more pronounced adverse effects occurred 
at smaller doses than is generally seen in studies with older subjects. The clinical message 
here seems clear; in accordance with clinical guidelines clinicians should consider using 
stimulants to treat ADHD in children from around the age of 6 years through to adulthood 
irrespective of age or sex. Stimulants should be used with caution in those under six years of 
age and probably reserved for those with severely impairing symptoms that have failed to 
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respond to non-pharmacological treatments. This last evidence-based recommendation also 
makes clinical sense as even though ADHD symptoms are usually apparent very early in life 
it is much more difficult to make a firm diagnosis of ADHD in the preschool child. It is 
difficult to recognise inattentive behaviours in preschoolers and there is a far wider variation 
in normal behaviour at this age. It is also the case that non-pharmacological behavioural 
interventions have been demonstrated to be effective in this age group and are likely to be 
safer especially where diagnostic uncertainty is present [138, 139]. 
Evidence suggests that, apart from in the preschool period, there are few age differences in 
response and tolerability for either MPH or AMP during childhood or adolescence and into 
early adulthood. Whilst both Taylor et al. (1987) and Buitelaar et al. (1995) found that 
younger age was associated with a better response these studies included relatively small 
samples with restricted age ranges. Neither of the two larger studies in children and young 
people [27, 111] found an effect of age on response. The finding reported by Ramos-Quiroga 
et al. (2009) that in their adult sample, the factors of older age and being male was associated 
with a better response are intriguing. This was a large study with a very broad range of ages 
and a high proportion of female subjects and clearly the results need to be taken seriously.  
Whilst these general recommendations may come as no surprise to many, they are important 
as they do not seem to reflect current routine clinical practice with respect to either sex or 
age. Data suggests that on top of the referral bias that sees boys with ADHD being more 
likely to be diagnosed than girls it seems that females that are diagnosed are less likely to be 
treated with stimulant medication than are their male counterparts [53]. Observational studies 
in clinical samples suggest that girls in Europe who are diagnosed with ADHD are as likely 
as boys to be prescribed stimulant medication as a first treatment [53].  Prescribing databases 
in the UK suggest that females are much less likely to be receiving prescriptions for stimulant 
medications than males with a ratio of male to female of 66:1 [45]. It is only possible to 
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speculate why this situation may have arisen. As girls often present with more inattentive 
symptoms and less oppositional and disruptive behaviours some clinicians may be reluctant 
to treat with stimulants mistakenly believing them only to be effective against the hyperactive 
and impulsive behaviours. It is also possible that whilst clinicians are recommending 
medication, it is the patients and/or their parents who themselves feel medication is less 
relevant for the types of problems girls are presenting with.  
Whilst the evidence presented in this review seems to make it unlikely that differential 
response rates or adverse effects could account for these differences, it is clear that stimulants 
work well in both sexes.  However, the findings of Sonuga Barke et al. (2007) highlight that 
overall response is only one aspect of successful treatment. Ideally treatment should be 
effective across as much of the day as possible. The introduction of the lab school protocol 
has allowed the PD of stimulant effects to be measured within a clinical trial. The data 
reported by Sonuga-Barke et al. (2007) suggest another possible route by which females may 
be ‘undertreated’ and less happy with their medication. This study reported that compared to 
males, females have a stronger early response to MPH, but that this effect also wears off 
more quickly in females than males. The reasons for these sex differences are unclear  but 
may be related to variations in sex differences in metabolism of MPH, the PK profile of MPH 
or differences in DA functioning between males and females [68]. These early and late day 
differences in drug effect were found to be independent of the two ER MPH preparations and 
suggest that females may require a different dosing strategy than males with a larger dose in 
the late afternoon. It is likely that working at such a level of detail regarding the profile of 
effects across the day is not a part of routine clinical practice. As is the case in clinical trials, 
clinicians are often asking the simpler question “is medication working?” rather than “is this 
medication working optimally across the day?” It is possible that such an approach would 
lead to a proportion of female patients who are well treated during the day having increased 
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difficulties at home in the late afternoon and evenings. In turn this could result in 
dissatisfaction with treatment, and for the patient and their family, an early discontinuation of 
a potentially helpful treatment. Author DC has developed a clinical tool, the Dundee Difficult 
Times of Day Scale (DDTODS; available from DC) that can help the clinician assess 
adequacy of treatment across the day and adjust treatment accordingly. It is interesting that 
the study of lisdexamfetamine, conducted by Wigal et al. (2009), which also used a lab-
school design to investigate sex effects did not find any differences between male and female 
participants with this AMF-pro drug. It is possible that this is a reflection of the interaction 
between sex and the different metabolic pathways for AMF and MPH drugs. AMF are 
primarily metabolized by the cytochrom-P450 isoenzyme 2D6 and MPH by carboxylesterase 
1A. The findings of both Sonuga-Barke et al. (2007) and Wigal et al. (2009) clearly need to 
be replicated and if the results are confirmed the reasons for the differences need to be 
carefully explored. 
When interpreting these findings we need to be aware of inherent limitations in the available 
literature. First, it has been noted already that very few studies were designed to address the 
issue of sex and age-related effects on stimulant response. This means that few studies were 
sufficiently powered to test for age and sex effects. In particular, they did not contain a 
sufficiently wide range of ages or a large enough number of female patients. Even where 
secondary analyses of the effects of sex and age were possible (as is the case for some of the 
recent large scale registration trials conducted by the pharmaceutical companies), there has 
often been a reluctance on the part of the companies to engage in the study of predictors of 
treatment response because of concern about potential product ‘niching’ (i.e., identifying sub-
groups for whom the project works best). Second, there are far fewer studies looking 
specifically at AMF products with regard to age and sex effects. Third, the outcome measures 
used in many studies have been rather limited in their range. The outcomes commonly used 
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were usually limited to parental, nursery/teacher reports on ADHD rating scales, with few 
examples of objective behavioural observations of core symptoms, standardised laboratory 
psychological tests or patient reported outcomes relating to broader outcomes such as quality 
of life [140]. It is possible that sex and age effects may emerge with different levels of 
measurement other core symptom changes. Fourth, few studies have employed 
methodologies that allow sex and age-related differences in PD to be examined. As can be 
seen from the lab school study reported by Sonuga-Barke et al. (2007) such studies have the 
power to identify more subtle differences between groups than is possible with the more 
general measures taken in most clinical trials. Finally, the effects of comorbidity as a 
confounding factor and/or a secondary outcome in sex and age effects have not been 
addressed to date.  
The key challenge for the future is therefore to design studies specifically to test the sex and 
age moderation hypotheses across a range of different stimulant and non-stimulant 
medications with equal numbers of male and female patients stratified for age and stage of 
development, and including measures relating to PD, neuropsychological functioning and 
quality of life as well as direct observation and symptom scales. Smaller scale studies should 
include PK and DA function measures and sex related biomarkers (such as hormonal levels 
and cycles) to examine the extent to which sex and age-related neurochemical effects mediate 
any clinical differences that might be observed.  
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